Immune-Based Intratumoral Cancer Therapies ft. Intensity Therapeutics founder and CEO Lewis Bender

In this episode, Ayesha had a conversation with Lewis Bender, MBA, Founder, Chairman and CEO of Intensity Therapeutics, a biotech company developing first-in-class immune-based intratumorally injected cancer therapies.

Intensity’s lead product candidate, INT230-6, is currently in human clinical studies for the treatment of refractory solid tumors, including metastatic soft tissue sarcoma and breast cancer.

Lewis Bender has almost three decades (28 years) of biopharmaceutical leadership experience and has helped take innovative new products from discovery through to product approval.

Lewis has held various leadership roles at biopharmaceutical companies including Interleukin Genetics and Emisphere Technologies. During his career, Lewis has partnered with several major pharmaceutical and biotech companies, with success raising capital from institutional investors through multiple types of transactions.

Tune into the episode, to hear more about the work Lewis is heading at Intensity Therapeutics to bring innovative, targeted intratumoral cancer therapies to patients.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured